Cancer Pain
Conditions
Keywords
hydromorphone titration
Brief summary
A large number of studies have shown that patients feel more satisfied with hydromorphone in the pain management. and a systematic review found that hydromorphone may be better suited than morphine for titration of acute analgesia. However, current researches on intravenous opioid titration for cancer pain such as hydromorphone are relatively insufficient in China. Therefore, a prospective, multi-center, randomized controlled study is conducted to assess the efficacy and safety of comparing patient-controlled analgesia (PCA) versus non-PCA intravenous hydromorphone titration for severe cancer pain.
Detailed description
The opioid dose for individual with cancer pain to provide adequate relief of pain with an acceptable degree of side effects is variable. Opioid titration is a process to obtain the tailored dose. Conventional titration is administered by a clinician or nurse. PCA is that patients control cancer pain by self-administration of intravenous opioids using programmable pump. The aim of our study is to evaluate the efficacy of PCA titration versus conventional titration intravenously for severe cancer pain (10-point numerical rating scale, NRS ≥ 7). Injectable Hydromorphone was selected as pharmaceutical analgesics, which works as well as morphine and oxycodone and had similar side effects.
Interventions
DRUGHydromorphone
1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes. 2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes.
DEVICEPCA pump
1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone. 2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs.
Sponsors
Fujian Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. With written informed consent signed voluntarily by patients themselves. 2. Cancer patients aged 18-70 years old. 3. Patients with cancer pain more than or equal to NRS 7 during previous 24 hours. 4. Patients who will not be treated with radiotherapy within 7 days prior to randomization and during study. 5. Patients who need chemotherapy, long term administration of hormone, targeted therapy, or bisphosphonates therapy should undergo a stable anti- tumor therapy prior to randomization. 6. Patients or his/her caregivers who are able to fill out the questionnaire forms. 7. Ability to correctly understand and cooperate with medication guidance of doctors and nurses. 8. Without a history of anaphylaxis of narcotic drugs. 9. Without psychiatric problems. 10. ECOG performance status ≤3. 11. Not participated in another drug clinical trial within one month before inclusion（including hydromorphone）.
Exclusion criteria
1. Patients diagnosed with non-cancer pain or unexplained pain. 2. Patients suffered with post-op pain. 3. Patients having paralytic ileus. 4. Patients who have hypersensitivity to hydromorphone. 5. There are abnormal lab results, with obvious clinical significance, such as the creatinine ≥ 2 fold of upper limit of normal value, or ALT or AST ≥ 2.5 fold of upper limit of normal value (≥ 5 fold,to the patients with liver metastasis or primary liver cancer), or liver function of Child C grade. 6. Patients having a incoercible Nausea and vomiting. 7. Monoamine oxidase inhibitor (MAOI) was administrated two week before randomization. 8. Patients who are pregnant or lactating,who plans to be pregnant within one month after the trial（including male）. 9. Patients who are opioid abuse. 10. Patients who are alcohol abuse. 11. Patients who are cognitive dysfunction. 12. Patients having a severe psychotic depression. 13. Patients with any other medical condition or reason, in that investigator's opinion, makes the patient unable to participate in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time of successful titration in 24 hours | In 24 hours | The satisfied pain control was defined NRS pain score ≤ 3 at rest in at least 2 consecutive assessment (15 minutes interval). The time needed to successful titration was extended to achieve satisfied pain control again if NRS pain score ≥ 7 after satisfied pain control within 24 hours. The failure of successful titration was defined that satisfied pain control does not achieve within 24 hours. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of patients titrated successfully within 24 hours | Up to 24 hours | The percentage of patients who titrated successfully within 24 hours |
| The mean NRS pain score of 24 hours | Up to 24 hours | The Numerical Rating Scale (NRS) is used to assess the severity of pain. The scale represents pain levels in 0-10 numbers, with 0 indicating no pain and 10 indicating the most severe pain. Ask the patient to choose the number that best represents his or her pain level, or ask the patient to ask: How severe is participant's pain? The health care provider selects the appropriate number based on the patient's description of the pain. 1-3 points indicate mild pain, 4-6 points indicate moderate pain, and 7-10 points indicate severe pain. The mean NRS pain score of 24 hrs is defined as the sum of the scores within 24 hours divided by the number of evaluations within 24 hours. |
| The total dose of hydromorphone titrated from start of titration to TST | Up to 24 hours | The total dose of hydromorphone titrated from start of titration to TST |
| The percentage of patients titrated successfully within 60 minutes | Up to 60 minutes | The percentage of patients who titrated successfully within 60 minutes |
| Improvement of patient symptoms | Up to 24 hours | The change from baseline in questionnaire: Chinese version of the Edmonton Symptom Assessment System |
| Adverse Events | Up to 7 days | treatment-related Adverse Events: |
| The total dose of hydromorphone titrated within 24 hrs | Up to 24 hours | The total dose of hydromorphone titrated within 24 hrs |
Countries
China
Outcome results
None listed